Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1-Specific CTL Immunotherapy for Advanced Leukemia/MDS Post-Transplant
NCT00052520Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2002
- Primary completion
- Apr 2011
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1-CTL in myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and 1 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Toxicity rate associated with infusing donor CD8+ CTL clones specific for WT1. Started Sep 2002; status: completed.
02
Drugs
WT1-CTL
03
Conditions
myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00052520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052520.